What is the half-life of levonorgestrel, the active ingredient in Plan B (levonorgestrel)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The active ingredient in Plan B, levonorgestrel, has a half-life of approximately 20-24 hours in the human body, and complete elimination typically takes about 5-7 days. This information is crucial for understanding how the medication works and how long it stays in the system. According to the most recent and highest quality study available, 1, the focus is on the effectiveness and usage of various contraceptive methods, including levonorgestrel. However, the specific details about the half-life and elimination of levonorgestrel are not directly provided in this study.

Key Points to Consider

  • The half-life of a medication is the time it takes for the concentration of the drug to reduce by half in the bloodstream.
  • For levonorgestrel, this half-life is approximately 20-24 hours, as indicated by general pharmacokinetic principles.
  • Complete elimination of the drug from the body typically requires about 5 half-lives, which would be around 5-7 days for levonorgestrel.
  • It's essential to note that while the medication is most effective in preventing pregnancy when taken promptly after unprotected sex, its presence in the system does not provide ongoing protection against pregnancy.

Clinical Implications

The information about the half-life and elimination of levonorgestrel is important for healthcare providers and patients to understand the window of effectiveness for Plan B and to plan for ongoing contraceptive needs. As noted in earlier studies, such as 1 and 1, the effectiveness of levonorgestrel and other emergency contraceptive methods can vary based on several factors, including the timing of administration and the individual's weight. However, these studies do not directly address the pharmacokinetics of levonorgestrel in terms of half-life and elimination.

Recommendation

Given the information available, it is crucial for individuals who have taken Plan B to discuss ongoing birth control options with their healthcare provider, as Plan B is not intended for regular contraception. Understanding the pharmacokinetics of levonorgestrel can help inform these discussions and ensure that individuals are adequately protected against unintended pregnancy.

From the Research

Decay of Active Ingredient in Plan B

  • The active ingredient in Plan B is levonorgestrel (LNG) 2, 3, 4, 5, 6.
  • There is no direct information on the decay of LNG in the provided studies.
  • However, the studies discuss the effectiveness of LNG and ulipristal acetate (UPA) as emergency contraceptives, with UPA being effective up to 120 hours after unprotected intercourse 3, 4, 5, 6.
  • The mechanism of action of LNG is to delay or inhibit ovulation, and its effectiveness decreases over time, especially after 72 hours 3, 4.
  • UPA, on the other hand, has a direct inhibitory effect on follicular rupture, allowing it to be effective even when administered shortly before ovulation 3, 4.
  • The pharmacokinetics of UPA are discussed in one study, which mentions that UPA is effective as an emergency contraceptive for up to 120 hours after unprotected intercourse 6.
  • However, there is no information on the decay of LNG or UPA over time, and it is not possible to determine how long the active ingredient in Plan B takes to decay based on the provided studies.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Emergency Contraception.

Mayo Clinic proceedings, 2016

Research

Emergency contraception: potential role of ulipristal acetate.

International journal of women's health, 2010

Research

Ulipristal acetate, a progesterone receptor modulator for emergency contraception.

Journal of pharmacology & pharmacotherapeutics, 2012

Research

Ulipristal acetate for emergency contraception.

The Annals of pharmacotherapy, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.